G Medical Innovations Holdings (G Medical Innovations Holdings) LT-Debt-to-Total-Asset : 0.06 (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is G Medical Innovations Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. G Medical Innovations Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2022 was 0.06.

G Medical Innovations Holdings's long-term debt to total assets ratio declined from Dec. 2021 (0.48) to Dec. 2022 (0.06). It may suggest that G Medical Innovations Holdings is progressively becoming less dependent on debt to grow their business.

G Medical Innovations Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for G Medical Innovations Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G Medical Innovations Holdings LT-Debt-to-Total-Asset Chart

G Medical Innovations Holdings Annual Data

Trend

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.31

0.18

0.09

0.48

0.06

G Medical Innovations Holdings Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial							0.09	0.02	0.48	0.09	0.06

G Medical Innovations Holdings LT-Debt-to-Total-Asset Calculation

G Medical Innovations Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )	/	Total Assets (A: Dec. 2022 )
	=	0.283	/	4.825
	=	0.06

G Medical Innovations Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (Q: Dec. 2022 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2022 )	/	Total Assets (Q: Dec. 2022 )
	=	0.283	/	4.825
	=	0.06

G Medical Innovations Holdings (OTCPK:GMVDF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

G Medical Innovations Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of G Medical Innovations Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

G Medical Innovations Holdings (G Medical Innovations Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » G Medical Innovations Holdings Ltd (OTCPK:GMVDF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Oppenheimer Street, Rehovot, ISR, 7670105

Website

https://www.gmedinnovations.com

G Medical Innovations Holdings Ltd is a mobile health (mHealth), telemedicine solutions, and monitoring service platforms. It develops and markets clinical and consumer medical-grade health monitoring solutions and offers end-to-end support for e-health projects. The company offers a suite of both consumer and clinical grade products and platforms which are positioned to reduce inefficiencies in healthcare delivery, improve access, reduce costs, increase the quality of care, and make healthcare more personalized and precise. Its operating segment includes Products, Patient Services, and Covid-19 testing. The company generates maximum revenue from the Patient Services segment.

Executives

Awm Investment Company, Inc.

10 percent owner

527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022